NCT06102395View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

PHASE3RecruitingINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2030

Conditions
Head and Neck Squamous Cell CarcinomaNeoadjuvant TherapyPembrolizumab
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200mg, IV, on day1 of Q3W, 2 cycle

DRUG

Cisplatin

Cisplatin 75 mg/m\^2, IV, day 1 of Q3W

DRUG

Carboplatin

Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W

DRUG

Nedaplatin

Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W

DRUG

Nab paclitaxel

Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W

DRUG

Docetaxel

Docetaxel 75 mg/m\^2, IV, day 1 of Q3W

DRUG

Liposomal paclitaxel

Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W

DRUG

Fluorouracil

Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W

Trial Locations (1)

100730

RECRUITING

Beijing Tongren Hospital, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER